Smithkline Beecham Corporation

Glaxosmithkline LLC

Martha A Sarpong

Kenneth Allen Newlander

Domingos J Silva

Nicholas D Adams

Cynthia A Parrish

Jerry Leroy Adams

Steven David Knight

Dashyant Dhanak

Joelle Lorraine Burgess

Jeffrey Michael Axten

Jun Tang

Stanley J Schmidt

Yanhong Feng

Michael Gerard Darcy

Amita M Chaudhari

Lance Howard Ridgers

Toshihiro Hamajima

Carla A Donatelli

Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.

Quinoline derivatives as P13 kinase inhibitors

Invented is a method of inhibiting the activity/function of PI3 kinases using quinoxaline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoxaline derivatives.

Quinoxaline derivatives as PI3 kinase inhibitors

The present invention relates to a compound represented by Formula (I): and pharmaceutically acceptable salts. Compounds of the present invention inhibit Aurora kinase, making them especially suitable for the treatment of a number of diseases, including solid tumor cancers and hematological cancers.

Azaindole inhibitors of aurora kinases

Growing community of inventors

Collegeville, PA, United States of America

Martha A Sarpong